{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T12:54:39Z","timestamp":1782996879720,"version":"3.54.5"},"reference-count":47,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2016,12,4]],"date-time":"2016-12-04T00:00:00Z","timestamp":1480809600000},"content-version":"vor","delay-in-days":3,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2016,12]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To characterize the use of tumor necrosis factor\u2010\u03b1 inhibitors (<jats:styled-content style=\"fixed-case\">TNFIs<\/jats:styled-content>) in children with juvenile idiopathic arthritis (<jats:styled-content style=\"fixed-case\">JIA<\/jats:styled-content>) and young adults with rheumatoid arthritis (<jats:styled-content style=\"fixed-case\">RA<\/jats:styled-content>).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients with incident <jats:styled-content style=\"fixed-case\">JIA<\/jats:styled-content> or <jats:styled-content style=\"fixed-case\">RA<\/jats:styled-content> were identified by using the Truven Health MarketScan Commercial Claims and Encounters database from 2009 to 2013. The incident diagnosis was defined as no prior claims with a <jats:styled-content style=\"fixed-case\">JIA<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">RA<\/jats:styled-content> code and no <jats:styled-content style=\"fixed-case\">JIA<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">RA<\/jats:styled-content> medications recorded during the previous 6 months. <jats:styled-content style=\"fixed-case\">TNFI<\/jats:styled-content> use patterns were examined, including switching among <jats:styled-content style=\"fixed-case\">TNFI<\/jats:styled-content>s, adherence, persistence, and time from diagnosis to <jats:styled-content style=\"fixed-case\">TNFI<\/jats:styled-content> use. Earlier <jats:styled-content style=\"fixed-case\">TNFI<\/jats:styled-content> treatment without prior use of traditional disease\u2010modifying antirheumatic drugs (<jats:styled-content style=\"fixed-case\">DMARDs<\/jats:styled-content>) and use of specific <jats:styled-content style=\"fixed-case\">TNFI<\/jats:styled-content>s were analyzed by age group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 6929 children and young adults with new diagnoses of <jats:styled-content style=\"fixed-case\">JIA<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">RA<\/jats:styled-content>, 18.6% were treated with <jats:styled-content style=\"fixed-case\">TNFI<\/jats:styled-content>s. In these <jats:styled-content style=\"fixed-case\">TNFI<\/jats:styled-content> users, 39.1% received earlier <jats:styled-content style=\"fixed-case\">TNFI<\/jats:styled-content> therapy without prior use of <jats:styled-content style=\"fixed-case\">DMARD<\/jats:styled-content>s. The use of <jats:styled-content style=\"fixed-case\">TNFI<\/jats:styled-content>s was higher in patients diagnosed between 2012 and 2013 than that in patients diagnosed between 2009 and 2011 (hazard ratio 1.13, 95% <jats:styled-content style=\"fixed-case\">confidence interval<\/jats:styled-content> 1.00\u20131.28). Etanercept was the most commonly used, especially by children aged &lt; 12 (75.5%) and adolescents aged 12 to 17 (62.5%) years. Adherence measured as mean proportion of days covered ranged from 70.4% to 93.2% for individual <jats:styled-content style=\"fixed-case\">TNFI<\/jats:styled-content> agents. Only about 60% of patients continuously took <jats:styled-content style=\"fixed-case\">TNFI<\/jats:styled-content>s for 12 months. When switching occurred, switching from etanercept to adalimumab was the most common pattern.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Earlier <jats:styled-content style=\"fixed-case\">TNFI<\/jats:styled-content> therapy was observed in 39.1% of children and young adults taking <jats:styled-content style=\"fixed-case\">TNFI<\/jats:styled-content>s. In addition, the time to the first <jats:styled-content style=\"fixed-case\">TNFI<\/jats:styled-content> prescription became shorter over the study period. Future research should evaluate the long\u2010term effectiveness and safety of this more aggressive <jats:styled-content style=\"fixed-case\">TNFI<\/jats:styled-content> therapy.<\/jats:p><\/jats:sec>","DOI":"10.1002\/phar.1856","type":"journal-article","created":{"date-parts":[[2016,10,25]],"date-time":"2016-10-25T11:27:55Z","timestamp":1477394875000},"page":"1201-1209","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Use of Tumor Necrosis Factor\u2010Alpha Inhibitors in Children and Young Adults With Juvenile Idiopathic Arthritis or Rheumatoid Arthritis"],"prefix":"10.1002","volume":"36","author":[{"given":"Wan\u2010Ju","family":"Lee","sequence":"first","affiliation":[{"name":"Department of Pharmacy Systems, Outcomes and Policy College of Pharmacy University of Illinois at Chicago Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Briars","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice College of Pharmacy University of Illinois at Chicago Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd A.","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Systems, Outcomes and Policy College of Pharmacy University of Illinois at Chicago Chicago Illinois"},{"name":"Center for Pharmacoepidemiology and Pharmacoeconomic Research College of Pharmacy University of Illinois at Chicago Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory S.","family":"Calip","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Systems, Outcomes and Policy College of Pharmacy University of Illinois at Chicago Chicago Illinois"},{"name":"Center for Pharmacoepidemiology and Pharmacoeconomic Research College of Pharmacy University of Illinois at Chicago Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie J.","family":"Suda","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Systems, Outcomes and Policy College of Pharmacy University of Illinois at Chicago Chicago Illinois"},{"name":"Center for Pharmacoepidemiology and Pharmacoeconomic Research College of Pharmacy University of Illinois at Chicago Chicago Illinois"},{"name":"Center of Innovation for Complex Chronic Healthcare Hines VA Hospital Hines Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glen T.","family":"Schumock","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Systems, Outcomes and Policy College of Pharmacy University of Illinois at Chicago Chicago Illinois"},{"name":"Center for Pharmacoepidemiology and Pharmacoeconomic Research College of Pharmacy University of Illinois at Chicago Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,12,4]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60363-8"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780390817"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.120661"},{"issue":"3","key":"e_1_2_6_5_1","first-page":"367","article-title":"Juvenile arthritis\u2013who gets it, where and when? A review of current data on incidence and prevalence","volume":"17","author":"Andersson Gare B","year":"1999","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"e_1_2_6_6_1","first-page":"499","article-title":"Epidemiology of rheumatoid arthritis, juvenile idiopathic arthritis and gout in two regions of the Czech Republic in a descriptive population\u2010based survey in 2002\u20132003","volume":"24","author":"Hanova P","year":"2006","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22463"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/39.2.198"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.10444"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/41.12.1428"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.008516"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-013-0023-7"},{"issue":"5","key":"e_1_2_6_13_1","first-page":"863","article-title":"The economic burden of juvenile idiopathic arthritis\u2010results from the German paediatric rheumatologic database","volume":"27","author":"Minden K","year":"2009","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq432"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-015-0508-1"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.20217"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200003163421103"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.134254"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60998-8"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0706290"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.101195"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20460"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.080889"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2012-002468"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.140012"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.34343"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.143347"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-201066"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-014-0417-8"},{"key":"e_1_2_6_30_1","unstructured":"DanielsonE.White Paper. Health Research Data for the Real World: The MarketScan Databases. 2011. Available at:http:\/\/truvenhealth.com\/portals\/0\/assets\/PH_11238_0612_TEMP_MarketScan_WP_FINAL.pdfAccessed on March 23 2016."},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-014-3142-8"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0b013e318214b6b5"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.10.115"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2006.00139.x"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.2165\/11532610-000000000-00000"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.120110"},{"issue":"10","key":"e_1_2_6_37_1","first-page":"274","article-title":"Effects of switching from etanercept to adalimumab in juvenile idiopathic arthritis. [abstract]","volume":"63","author":"Horneff G","year":"2011","journal-title":"Arthritis Rheum"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev429"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204641"},{"issue":"6","key":"e_1_2_6_40_1","first-page":"S136","article-title":"Treatment compliance and dosage administration among rheumatoid arthritis patients receiving infliximab, etanercept, or methotrexate","volume":"9","author":"Harley CR","year":"2003","journal-title":"Am J Manag Care"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2010.00764.x"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007990902896386"},{"key":"e_1_2_6_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-010-1774-x"},{"key":"e_1_2_6_44_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22104"},{"key":"e_1_2_6_45_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-014-0410-2"},{"key":"e_1_2_6_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2005.11.002"},{"key":"e_1_2_6_47_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-199909000-00002"},{"key":"e_1_2_6_48_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.mlr.0000207817.32496.cb"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fphar.1856","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fphar.1856","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.1856","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:06:38Z","timestamp":1761048398000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.1856"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":47,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["10.1002\/phar.1856"],"URL":"https:\/\/doi.org\/10.1002\/phar.1856","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"2016-12-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}